|
|
I'm trying to visualize what's going to happen if/when H5N1 mutates to a
person-to-person-transmissible virus.
One image I have is of a very rapid spread because nobody has any existing
immunity. i.e. Lots of people that we have contact with going about our daily
business are going to be coming down with it.
Given that, if somebody became infected and lived; it seems like they would
still be encountering other infected people on a fairly regular basis after
that.
So: if that infected person had access to an antiviral drug that enabled them to
survive the first infection, would they then have an immunity to the virus
comparable to having received a vaccination? .... or would they require access
to additional courses of the antiviral drug in order to survive subsequent
re-infections?
--
PeteCresswell
|
|